Scarica l'app Stockscreener
0.00
100.00%
-1.35
Precedente Chiudi:
$1.35
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$8.52M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$3.80
Chromocell Therapeutics Corp Stock (CHRO) Company Profile
Nome
Chromocell Therapeutics Corp
Settore
Industria
Telefono
(917) 644-6313
Indirizzo
685 US HIGHWAY ONE, NORTH BRUNSWICK
Confronta CHRO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CHRO
Chromocell Therapeutics Corp
|
0.00 | 8.52M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Chromocell Therapeutics Corp Borsa (CHRO) Ultime notizie
Pelthos Therapeutics target adjusted at Alliance after merger, reverse split - TipRanks
Pelthos Therapeutics shares rise 6.99% after-hours following CEO changes announcement. - AInvest
Pelthos Therapeutics Inc. announced that it has received $50 million in funding from Murchinson Ltd. and other investors - MarketScreener
Ligand Unit Completes Merger With Channel Subsidiary to Form Pelthos Therapeutics - MarketScreener
Channel Therapeutics Announces Reverse Common Stock Split - GlobeNewswire
Channel Therapeutics Faces Financial Uncertainty as Auditors Issue Going Concern Warning - Stock Titan
Ligand Pharmaceuticals to Merge Units With Channel Therapeutics to Launch Pelthos Therapeutics - marketscreener.com
Gold Falls Over 1%; D.R. Horton Posts Downbeat Earnings - Benzinga
Ligand subsidiaries, Chromocell Therapeutics to merge - TipRanks
Ligand Subsidiary Pelthos Therapeutics To Combine With Channel Therapeutics - marketscreener.com
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics - GlobeNewswire Inc.
Channel Therapeutics Corporation announced that it has received $0.25 million in funding -February 24, 2025 - Marketscreener.com
Channel Therapeutics secures $325,000 promissory note By Investing.com - Investing.com Australia
Channel Therapeutics secures $325,000 promissory note - Investing.com India
New Biotech Stocks at Investorideas.com - Investorideas.com newswire
Biopharma IPOs rebound slightly, as class of 2024 lags with a 29% average decline - BioWorld MedTech
Channel Therapeutics Advances Novel Pain Treatment Strategy with NaV1.7 Inhibitor Pipeline - Stock Titan
Chromocell Announces Name Change to “Channel Therapeutics Corporation” and Provides Therapeutic Program Updates - Yahoo Finance
Channel Therapeutics finalizes corporate restructuring - Investing.com
Chromocell Announces Amendment to Stock Repurchase Plan - The Manila Times
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing - GlobeNewswire
Chromocell to Participate in Life Sciences Investor Forum September 19th - Yahoo Finance
CDMO Benuvia Appoints Terry Novak As New CEO - Pharmaceutical Online
IPO class of 2024 shows value recovery despite mixed stock performance - BioWorld MedTech
Healthy Returns: Biotech IPOs ramped up to start 2024, but the market hasn't fully recovered just yet - CNBC
Why Super Micro Computer Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session - TradingView
Chutes & Ladders—Bayer undergoes leadership shake-up - Fierce Biotech
Are there bright times for biotech IPOs ahead? - European Biotechnology Magazine
Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023 - MarketScreener
Chromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 Million - Yahoo Finance
CHRO Stock Price and Chart — AMEX:CHRO - TradingView
Pelthos Therapeutics Inc Stock Price Today | NYSE: PTHS Live - Investing.com
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering - Yahoo Finance
CHRO IPO NewsPain relief biotech Chromocell Therapeutics sets terms for $9 million IPO - renaissancecapital.com
Biotech Venture in the UAE Validated by IPO in the U.S. - PR Newswire
Tina Garyantes – Feliciano Center For Entrepreneurship And Innovation - Montclair State University
Nestlé and Chromocell Extend Collaboration to Find Alternatives to Salt - Food Manufacturing
Improving the Reliability and Utility of Streptozotocin‐Induced Rat Diabetic Model - Wiley Online Library
Chromocell Announces Initiation of Multiple Ascending Doses Portion of Phase 1 Clinical Trial - PR Newswire
Chromocell and Astellas Announce FDA Fast Track Designation and First Subject Dosing with Lead Candidate CC8464/ASP1807 for the Management of Neuropathic Pain Associated with iSFN - PR Newswire
News from Central Jersey's pharma, biotech industries - Central New Jersey News
Astellas, Chromocell Launch Up-to-$515M+ Pain Drugs Collaboration - Genetic Engineering and Biotechnology News
Chromocell Therapeutics Corp Azioni (CHRO) Dati Finanziari
Non sono disponibili dati finanziari per Chromocell Therapeutics Corp (CHRO). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.96%
1.09%
Capitalizzazione:
|
Volume (24 ore):